Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Vascular Biogenics stock

Learn how to easily invest in Vascular Biogenics stock.

Vascular Biogenics Ltd is a biotechnology business based in the US. Vascular Biogenics shares (VBLT) are listed on the NASDAQ and all prices are listed in US Dollars. Vascular Biogenics employs 41 staff and has a trailing 12-month revenue of around $572,000.

How to buy shares in Vascular Biogenics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VBLT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Vascular Biogenics stock price (NASDAQ: VBLT)

Use our graph to track the performance of VBLT stocks over time.

Vascular Biogenics shares at a glance

Information last updated 2022-10-03.
Latest market close$0.17
52-week range$0.15 - $2.54
50-day moving average $0.21
200-day moving average $1.23
Wall St. target price$5.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.47

Buy Vascular Biogenics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vascular Biogenics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vascular Biogenics price performance over time

Historical closes compared with the close of $0.17 from 2022-10-04

1 week (2022-09-28) 6.92%
1 month (2022-09-02) -18.27%
3 months (2022-07-05) -90.23%
6 months (2022-04-05) -90.29%
1 year (2021-10-05) -91.63%
2 years (2020-10-05) -85.34%
3 years (2019-10-04) 1.28
5 years (2017-10-05) 6.1

Vascular Biogenics financials

Revenue TTM $572,000
Gross profit TTM $403,000
Return on assets TTM -39.73%
Return on equity TTM -80.04%
Profit margin 0%
Book value $0.50
Market capitalisation $11.1 million

TTM: trailing 12 months

Vascular Biogenics share dividends

We're not expecting Vascular Biogenics to pay a dividend over the next 12 months.

Vascular Biogenics share price volatility

Over the last 12 months, Vascular Biogenics's shares have ranged in value from as little as $0.145 up to $2.54. A popular way to gauge a stock's volatility is its "beta".

VBLT.US volatility(beta: 0.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vascular Biogenics's is 0.5605. This would suggest that Vascular Biogenics's shares are less volatile than average (for this exchange).

Vascular Biogenics overview

Vascular Biogenics Ltd. , a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd.

Frequently asked questions

What percentage of Vascular Biogenics is owned by insiders or institutions?
Currently 23.218% of Vascular Biogenics shares are held by insiders and 20.524% by institutions.
How many people work for Vascular Biogenics?
Latest data suggests 41 work at Vascular Biogenics.
When does the fiscal year end for Vascular Biogenics?
Vascular Biogenics's fiscal year ends in December.
Where is Vascular Biogenics based?
Vascular Biogenics's address is: 8 HaSatat Street, Hevel Modi'in, Israel, 7178106
What is Vascular Biogenics's ISIN number?
Vascular Biogenics's international securities identification number is: IL0011327454
What is Vascular Biogenics's CUSIP number?
Vascular Biogenics's Committee on Uniform Securities Identification Procedures number is: M96883109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site